Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study

MLA

Lawrence Einhorn, et al. “Phase III Trial of Cyclophosphamide versus Cyclophosphamide, Doxorubicin, and Methotrexate in Hormone-Refractory Prostatic Cancer. A Hoosier Oncology Group Study.” Cancer, vol. 70, no. 10, Nov. 1992. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3e3b5635cc16ad43dc8a371669456dfe&authtype=sso&custid=ns315887.

APA

Lawrence Einhorn, Michael D. Miller, Rafat Ansari, Ben Wheeler, John McClean, Ray Drasga, & Scott Saxman. (1992). Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study. Cancer, 70(10).

Chicago

Lawrence Einhorn, Michael D. Miller, Rafat Ansari, Ben Wheeler, John McClean, Ray Drasga, and Scott Saxman. 1992. “Phase III Trial of Cyclophosphamide versus Cyclophosphamide, Doxorubicin, and Methotrexate in Hormone-Refractory Prostatic Cancer. A Hoosier Oncology Group Study.” Cancer 70 (10). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3e3b5635cc16ad43dc8a371669456dfe&authtype=sso&custid=ns315887.